Literature DB >> 29572163

The cardiac proteome in patients with congenital ventricular septal defect: A comparative study between right atria and right ventricles.

A R Bond1, D Iacobazzi1, S Abdul-Ghani1, M T Ghorbel1, K J Heesom2, S J George1, M Caputo3, M-S Suleiman1, R M Tulloh4.   

Abstract

Right ventricle (RV) remodelling occurs in neonatal patients born with ventricular septal defect (VSD). The presence of a defect between the two ventricles allows for shunting of blood from the left to right side. The resulting RV hypertrophy leads to molecular remodelling which has thus far been largely investigated using right atrial (RA) tissue. In this study we used proteomic and phosphoproteomic analysis in order to determine any difference between the proteomes for RA and RV. Samples were therefore taken from the RA and RV of five infants (0.34 ± 0.05 years, mean ± SEM) with VSD who were undergoing cardiac surgery to repair the defect. Significant differences in protein expression between RV and RA were seen. 150 protein accession numbers were identified which were significantly lower in the atria, whereas none were significantly higher in the atria compared to the ventricle. 19 phosphorylation sites (representing 19 phosphoproteins) were also lower in RA. This work has identified differences in the proteome between RA and RV which reflect differences in contractile activity and metabolism. As such, caution should be used when drawing conclusions based on analysis of the RA and extrapolating to the hypertrophied RV. SIGNIFICANCE: RV hypertrophy occurs in neonatal patients born with VSD. Very little is known about how the atria responds to RV hypertrophy, especially at the protein level. Access to tissue from age-matched groups of patients is very rare, and we are in the unique position of being able to get tissue from both the atria and ventricle during reparative surgery of these infants. Our findings will be beneficial to future research into heart chamber malformations in congenital heart defects.
Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Congenital heart disease; Proteomics; Right atria; Right ventricle; Ventricular septal defect

Mesh:

Substances:

Year:  2018        PMID: 29572163     DOI: 10.1016/j.jprot.2018.03.022

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  4 in total

1.  Deep sequencing unveils altered cardiac miRNome in congenital heart disease.

Authors:  Vinu Ramachandran; Sambhavi Bhagavatheeswaran; Sambantham Shanmugam; Madavan Vasudevan; Malathi Ragunathan; Kotturathu Mammen Cherian; Arasambattu Kannan Munirajan; Sudesh Ravi; Anandan Balakrishnan
Journal:  Mol Genet Genomics       Date:  2022-06-07       Impact factor: 2.980

2.  Changes in inflammation and oxidative stress signalling pathways in coarcted aorta triggered by bicuspid aortic valve and growth in young children.

Authors:  Katie L Skeffington; Andrew R Bond; M Giulia Bigotti; Safa AbdulGhani; Dominga Iacobazzi; Sok-Leng Kang; Kate J Heesom; Marieangela C Wilson; Serban Stoica; Robin Martin; Massimo Caputo; M Saadeh Suleiman; Mohamed T Ghorbel
Journal:  Exp Ther Med       Date:  2020-09-03       Impact factor: 2.447

3.  Bicuspid Aortic Valve Alters Aortic Protein Expression Profile in Neonatal Coarctation Patients.

Authors:  Katie L Skeffington; Andrew R Bond; Safa Abdul-Ghani; Dominga Iacobazzi; Sok-Leng Kang; Kate J Heesom; Marieangela C Wilson; Mohamed Ghorbel; Serban Stoica; Robin Martin; M Saadeh Suleiman; Massimo Caputo
Journal:  J Clin Med       Date:  2019-04-16       Impact factor: 4.241

4.  Effect of cardioplegic arrest and reperfusion on left and right ventricular proteome/phosphoproteome in patients undergoing surgery for coronary or aortic valve disease.

Authors:  Safa Abdul-Ghani; Katie L Skeffington; Minjoo Kim; Marco Moscarelli; Philip A Lewis; Kate Heesom; Francesca Fiorentino; Costanza Emanueli; Barnaby C Reeves; Prakash P Punjabi; Gianni D Angelini; M-Saadeh Suleiman
Journal:  Int J Mol Med       Date:  2022-04-15       Impact factor: 5.314

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.